NextCure, Inc.NXTCNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank75
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-0.33
↑ 96% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-8.87
Historical baseline
PeriodValueYoY Change
2025-0.33-8272.2%
20240.00+101.0%
2023-0.39-44.6%
2022-0.27+88.1%
2021-2.30+67.8%
2020-7.16+70.9%
2019-24.58-63.3%
2018-15.05+49.3%
2017-29.70-